Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Nutrient status: Vitamins, minerals, trace elements at baseline, after 10, 20, and 40 weeks of the MoKaRi studyParameterwkMP group (n = 26)Characteristics*p value within groupMP-FO group (n = 25)Characteristics*p value within groupp value between groupsBiotin(ng/l)0377.4 (± 127.7)338.0 (297.5, 445.5)a,b352.9 (± 135.0)299.0 (258.5, 442.0)an.s.10405.0 (336.0, 532.5)a294.0 (248.8, 404.0)an.s.20331.0 (296.0, 505.5)a,b349.0 (234.5, 540.8)an.s.40318.0 (253.5, 486.0)b237.5 (172.0, 309.3)b0.039Cfb∆−2.5 (−19.2, 31.0)2.49 (−35.6, 35.7)n.s.Folic acid(ng/ml)010.2 (± 4.3)9.9 (6.9, 12.5)a9.7 (± 3.4)8.7 (7.5, 12.7)an.s.109.7 (7.6, 12.1)a8.7 (7.1, 11.3)an.s.2010.5 (7.7, 13.1)a8.4 (7.3, 12.1)an.s.408.4 (6.9, 10.7)a9.5 (7.6, 11.6)an.s.Cfb∆4.5 (−6.9, 29.6)−5.6 (−17.6, 21.7)n.s.Vitamin B1(nmol/l)0134.5 (122.7, 145.1)a,b134.5 (115.6, 139.7)an.s.10132.1 (± 19.9)129.2 (117.1, 144.1)a125.0 (± 17.1)123.1 (114.9, 135.7)an.s.20128.4 (± 19.2)126.3 (115.7, 138.4)a126.4 (± 19.7)125.5 (112.7, 142.9)an.s.40154.5 (134.9, 163.9)b150.2 (142.9, 161.8)bn.s.Cfb∆−3.6 (± 19.2)−2.9 (± 15.2)n.s.Vitamin B2(µg/l)0216.5 (± 39.1)224.0 (199.0, 230.0)a237.9 (± 54.1)an.s.10238.0 (215.0, 271.5)a241.6 (± 37.5)an.s.20222.0 (209.0, 244.0)a235.3 (± 41.8)an.s.40255.0 (229.5, 270.5)a225.6 (± 66.1)an.s.Cfb∆7.6 (−1.5, 24.5)2.0 (−10.7, 14.8)n.s.Vitamin B6(nmol/l)049.0 (37.6, 70.2)a53.2 (37.2, 72.5)an.s.1050.2 (35.3, 69.5)a66.2 (50.2, 84.9)bn.s.2053.2 (38.0, 88.0)a65.3 (50.1, 83.1)bn.s.4068.1 (48.8, 102.5)a53.6 (39.2, 70.4)an.s.Cfb∆16.6 (−7.8, 43.3)34.7 (7.9, 70.7)n.s.Vitamin B12(pmol/l)0271.0 (238.0, 312.0)a250.0 (221.0, 280.0)an.s.10248.0 (233.5, 303.5)a262.0 (225.5, 325.5)a,bn.s.20282.3 (± 70.2)279.0 (228.5, 334.0)a269.7 (± 91.8)256.0 (207.5, 314.5)an.s.40331.2 (± 76.6)317.0 (278.5, 392.5)b304.0 (± 86.9)304.0 (237.5, 361.0)bn.s.Cfb∆−1.9 (−17.0, 8.8)2.8 (−10.7, 16.4)n.s.Holo-TC(pmol/l)0120.6 (101.2, 137.3)a110.2 (92.4, 146.4)an.s.10107.9 (88.3, 120.0)a111.9 (78.8, 125.6)bn.s.20110.6 (96.8, 124.4)a101.20(79.1, 121.6)bn.s.40121.6 (± 33.9)118.8 (106.2, 142.1)a114.4 (± 29.2)119.5 (98.3, 132.7)an.s.Cfb∆−8.3 (−21.1, 3.8)−14.1 (−24.9, 1.4)n.s.Vitamin C(mg/l)05.4 (3.7, 6.9)a4.4 (2.6, 5.2)an.s.105.2 (4.1, 6.9)a4.5 (3.3, 6.0)a,bn.s.207.5 (± 3.5)7.7 (4.4, 8.7)a8.3 (± 2.7)8.8 (6.8, 9.6)cn.s.407.1 (4.9, 10.1)a7.2 (4.3, 10.7)b,cn.s.Cfb∆39.1 (−30.8, 125.8)66.7 (19.3, 183.9)n.s.Retinol(µmol/L)03.35 (± 0.89)a2.90 (± 0.49)an.s.103.24 (± 0.79)a2.67 (± 0.36)a0.018203.06 (± 0.85)a2.80 (± 0.36)an.s.403.32 (± 0.71)a3.11 (± 0.68)an.s.Cfb∆0.43 (−19.76, 10.28)−3.69 (−11.77, 6.10)n.s.alpha-carotene(µmol/L)00.19 (0.14, 0.31)a0.27 (0.21, 0.44)an.s.100.22 (0.14, 0.35)a0.39 (0.20, 0.65)an.s.200.25 (0.15, 0.39)a0.49 (0.29, 0.67)a0.010400.34 (0.21, 0.41)a0.50 (0.33, 0.61)a0.037Cfb∆8.56 (−17.68, 51.16)41.61 (−4.26, 119.89)n.s.beta-carotene(µmol/L)00.41 (± 0.26)0.33 (0.23, 0.59)a0.50 (0.31, 0.88)an.s.100.46 (± 0.21)a0.88 (± 0.59)0.69 (0.50, 1.12)a,b0.021200.48 (± 0.29)0.36 (0.32, 0.62)a0.83 (0.62, 0.92)b0.004400.50 (± 0.20)0.46 (0.36, 0.61)a0.71 (0.57, 0.93)b0.008Cfb∆23.42 (−20.97, 64.79)34.62 (11.28, 60.39)n.s.Lutein pluszeaxanthin (µmol/L)00.71 (0.54, 0.82)a0.81 (0.62, 1.18)an.s.100.77 (± 0.34)0.71 (0.54, 0.88)a0.96 (± 0.35)1.03 (0.76, 1.20)an.s.200.68 (± 0.26)0.76 (0.48, 0.88)a0.94 (± 0.33)0.90 (0.78, 1.15)a0.021400.67 (0.58, 0.81)a1.02 (0.71, 1.25)a0.023Cfb∆−3.01 (−36.38, 22.94)4.35 (−15.18, 34.04)n.s.beta-cryptoxanthin(µmol/L)00.18 (± 0.12)0.17 (0.07, 0.28)a0.39 (± 0.19)0.37 (0.22, 0.56)an.s.100.14 (0.10, 0.19)a0.29 (0.18, 0.39)a0.001200.12 (0.06, 0.18)a0.20 (0.16, 0.29)b0.005400.13 (0.12, 0.18)a0.22 (0.18, 0.28)b0.014Cfb∆−24.79 (−55.26, 5.00)−38.06 (−57.30, −17.13)n.s.Lycopene(µmol/L)00.13 (± 0.09)0.11 (0.07, 0.18)a0.18 (± 0.11)an.s.100.11 (0.07, 0.24)a0.19 (± 0.11)0.15 (0.12, 0.29)an.s.200.16 (± 0.09)0.13 (0.09, 0.21)a0.25 (± 0.13)a0.020400.11 (0.08, 0.22)a0.26 (± 0.14)0.25 (0.13, 0.35)a0.015Cfb∆46.29 (−27.19, 134.28)29.74 (11.57, 94.68)n.s.Vitamin D(nmol/l)049.0 (37.3, 65.3)a43.3 (28.1, 64.5)an.s.1054.5 (40.1, 71.1)a42.0 (30.0, 52.0)an.s.2063.5 (55.3, 78.4)b59.4 (45.1, 73.1)bn.s.4062.7 (54.7, 73.7)b60.5 (44.9, 72.6)bn.s.Cfb∆17.4 (7.9, 76.2)34.6 (8.5, 55.7)n.s.gamma-tocopherol(µmol/L)03.1 (2.4, 3.3)a,b3.2 (± 0.6)3.2 (3.0, 3.4)an.s.102.6 (2.2, 3.0)a2.6 (± 0.5)2.5 (2.2, 3.0)bn.s.202.8 (2.4, 3.1)a,b2.8 (± 0.7)2.7 (2.3, 3.1)bn.s.403.4 (± 1.1)3.3 (2.5, 3.9)b3.2 (± 0.6)an.s.Cfb∆−6.1 (± 18.7)−10.9 (± 13.6)n.s.alpha-tocopherol(µmol/L)026.2 (± 11.9)a34.4 (± 8.5)33.8 (28.5, 42.4)a0.0361025.1 (± 9.7)23.2(18.8, 28.0)a22.9 (20.5, 30.6)b,cn.s.2023.8 (± 14.9)22.0 (14.0, 30.9)a25.2 (22.1, 27.9)cn.s.4027.7 (± 12.8)a29.9 (± 9.0)29.4 (24.5, 33.3)a,bn.s.Cfb∆−8.5 (−32.0, 13.2)−27.5 (−40.6, −4.3)n.s.Calcium(mmol/l)02.5 (± 0.1)a2.4 (± 0.1)an.s.102.4 (± 0.1)b2.3 (± 0.1)bn.s.202.4 (± 0.1)b2.3 (± 0.1)bn.s.402.4 (± 0.1)b2.3 (± 0.1)bn.s.Cfb∆−3.5 (−6.0, −0.9)−2.9 (−5.2, 0.0)n.s.Potassium(mmol/l)04.1 (3.9, 4.3)a4.1 (± 0.5)4.2 (3.9, 4.2)an.s.103.9 (3.8, 4.2)a3.9 (± 0.3)3.9 (3.7, 4.1)bn.s.204.0 (± 0.3)4.0 (3.8, 4.2)a4.0 (± 0.3)a,bn.s.404.1 (± 0.4)4.1 (3.8, 4.3)a4.0 (± 0.3)a,bn.s.Cfb∆−3.2 (−7.2, 0.2)−3.1 (−6.4, 0.8)n.s.Iron(µmol/l)019.7 (15.9, 21.5)a18.7 (± 4.8)18.5 (15.3, 20.9)an.s.1015.3 (13.2, 18.5)a14.7 (± 4.8)14.0 (10.8, 18.5)bn.s.2016.0 (14.6, 19.7)a15.1 (± 4.2)14.7 (12.1, 16.4)bn.s.4017.8 (± 5.7)17.9 (13.5, 20.2)a17.6 (± 4.5)an.s.Cfb∆−12.8 (−34.3, 4.4)−23.9 (−36.2, −1.1)n.s.Ferritin(µg/l)081.0 (52.5, 189.9)a87.5 (52.1, 125.3)an.s.1064.3 (43.7, 111.8)b74.6 (35.5, 137.5)an.s.2049.1 (33.8, 96.8)c64.4 (29.6, 105.0)bn.s.4066.0 (42.9, 114.9)b,c72.9 (39.0, 114.5)bn.s.Cfb∆−37.2 (−52.3, −27.2)−36.8 (−48.5, −17.3)n.s.Transferrin(g/l)02.8 (± 0.5)a2.8 (± 0.4)an.s.102.6 (± 0.4)a2.7 (± 0.4)an.s.202.7 (± 0.5)a2.7 (± 0.3)an.s.402.7 (± 0.4)a2.7 (± 0.3)an.s.Cfb∆0.3 (± 7.0)0.1 (± 7.6)n.s.Iodine(µg/l)052.4 (48.5, 57.7)a,b58.1 (± 11.6)56.4 (48.6, 67.5)a,bn.s.1059.7 (49.0, 72.4)a64.2 (± 13.5)61.5 (54.2, 73.1)an.s.2049.3 (± 10.7)49.2 (44.9, 54.7)b54.9 (± 9.6)bn.s.4057.1 (± 9.2)55.6 (51.5, 62.2)a65.6 (± 15.6)a0.048Cfb∆−4.6 (± 19.4)−4.0 (± 17.5)n.s.Creatinine 24h urine(mmol/24h)010.0 (± 5.3)8.8 (6.0, 11.8)a10.3 (± 3.1)9.8 (7.9, 11.9)an.s.2010.6 (± 4.1)10.1 (8.3, 13.5)a9.5 (± 2.6)8.8 (7.9, 11.1)an.s.404.6 (3.6, 6.1)b5.2 (3.7, 6.9)bn.s.Cfb∆−1.1 (−18.0, 18.3)−4.7 (−20.5, 8.6)n.s.Methylmalonic acid 24 h urine(mmol/24h)01.3 (± 0.6)1.3 (1.0, 1.7)a1.6 (± 0.6)1.5 (1.3, 2.0)an.s.201.6 (± 0.6)1.7 (1.1, 2.1)a1.8 (± 0.7)1.7 (1.3, 2.4)an.s.401.6 (1.1, 2.1)a1.8 (1.1, 2.2)an.s.Cfb∆17.8 (−25.2, 60.2)13.4 (−8.4, 40.0)n.s.Magnesium 24h urine(mmol/24h)04.1 (± 2.04.1 (2.3, 5.7)a4.2 (± 1.5)4.2 (3.3, 5.3)an.s.204.2 (3.3, 5.4)a4.0 (3.2, 4.7)an.s.404.7 (± 2.3)4.4 (3.2, 6.4)a4.4 (± 1.4)4.6 (3.5, 5.4)an.s.Cfb∆7.7 (−12.2, 38.6)−0.7 (−21.0, 16.0)n.s.Sodium 24h urine(mmol/24h)0116.2 (± 50.0)114.5 (79.0, 149.0)a137.6 (± 47.1)an.s.20142.5 (88.3, 186.8)a121.9 (± 48.8)121.0 (85.0, 148.0)a,bn.s.4080.7 (± 31.1)80.0 (60.5, 102.8)b90.4 (± 50.7)bn.s.Cfb∆6.5 (−21.4, 47.6)0.33 (−44.7, 17.2)n.s.Selenium 24h urine(mmol/24h)00.16 (0.09, 0.19)a0.19 (0.14, 0.23)an.s.200.21 (0.16, 0.26)a,b0.23 (0.20, 0.31)an.s.400.27 (± 0.11)0.24 (0.19, 0.35)b0.30 (± 0.15)0.29 (0.18, 0.36)an.s.Cfb∆72.37 (± 110.47)73.12 (± 106.58)n.s.Zinc 24h urine(mmol/24h)06.8 (2.8, 7.6)a6.8 (4.1, 10.6)an.s.206.3 (3.5, 9.3)a5.5 (4.2, 9.3)an.s.407.2 (3.7, 12.2)a6.6 (4.5, 8.2)an.s.Cfb∆14.9 (−16.5, 31.3)−7.6 (−36.0, 28.0)n.s.Abbreviations: Cfb change from baseline, Holo-TC holo-transcobalamin* Variables expressed as mean (± SD) and/or as median (25th, 75th percentile) depending on the statistical test that was performed; Cfb∆ Percentage change between baseline and the end of the intervention (week 20); Points in time without a common letter are significantly different, p < 0.05.
Source: Effect of the MoKaRi diets on the status of vitamins and minerals. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
The participants were randomly assigned to two groups.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Reduction of cardiovascular risk factors by the diet: Evaluation of the MoKaRi concept by a parallel-designed randomized study
Study design awaiting verification · Lipids in Health and Disease · 2025
Original publication title
Reduction of cardiovascular risk factors by the diet: Evaluation of the MoKaRi concept by a parallel-designed randomized study
© The Author(s) 2025
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What methods does the paper describe?
For our 20-week intervention study, 65 participants with moderate elevated low-density lipoprotein cholesterol (LDL-C; ≥ 3 mmol/l) and without lipid-lowering therapy were recruited. The intervention to improve nutritional behavior was based on individualized menu plans which were characterized by defined energy and nutrient intake. To improve compliance, individual nutritional counselling sessions were held every two weeks. In addition to motivation, cooking skills were strengthened and nutritional knowledge was imparted. Follow-up visits were carried out after 10 and 20 weeks.
Source: MethodsAbstract: Background and aim
The MoKaRi study aims to evaluate the impact of two nutritional concepts on cardiometabolic risk factors.
Source: Background and aimAbstract: ClinicalTrials.gov Identifier
NCT02637778.
Source: ClinicalTrials.gov IdentifierAbstract: Results
The MoKaRi diet lowered the concentrations of total cholesterol (menu plan group (MP): -15%; menu plan plus fish oil group (MP-FO): -11%), LDL-C (MP: -14%; MP-FO: -16%) and non-high-density lipoprotein cholesterol (MP: -16%; MP-FO: -13%) (p < 0.001). Body weight (MP: -5%; MP-FO: -8%; p < 0.05), waist circumference (MP: -6%; MP-FO: -9%) as well as diastolic blood pressure (MP: -8%; MP-FO: -8%), apolipoprotein A1 (MP: -15%; MP-FO: -20%), apolipoprotein B (MP: -15%; MP-FO: -6%) and glycated hemoglobin A1c (HbA1c) (MP: -1.8%; MP-FO: -3.6%) were also reduced in both groups after 20 weeks (p < 0.05).
In both intervention groups, a maximum reduction in LDL-c of approx. 26% was achieved within the 20 weeks of intervention. Individual participants achieved a reduction of 45 to 49%. The supplementation of fish oil on top of the menu plans resulted in more substantial effects on body weight (MP: -5% vs. MP-FO: -8%), body fat (MP: -11% vs. MP-FO: -20%), triglycerides (MP: -14% vs. MP-FO: -28%), high-sensitivity C-reactive protein (MP: -19% vs. MP-FO: -43%) and HbA1c (MP: -1.8% vs. MP-FO:: 3.6%; p < 0.05).
Source: ResultsAbstract: Conclusions
The MoKaRi diet resulted in a significant reduction of cardiometabolic risk factors. Our data highlights the additional benefit of the combination between menu plans and fish oil supplementation, which resulted in more substantial effects on body weight, BMI, TG, HbA1c and hs-CRP.
Source: ConclusionsAuthors’ abstract
Background and aim
The MoKaRi study aims to evaluate the impact of two nutritional concepts on cardiometabolic risk factors.
Methods
For our 20-week intervention study, 65 participants with moderate elevated low-density lipoprotein cholesterol (LDL-C; ≥ 3 mmol/l) and without lipid-lowering therapy were recruited. The intervention to improve nutritional behavior was based on individualized menu plans which were characterized by defined energy and nutrient intake. To improve compliance, individual nutritional counselling sessions were held every two weeks. In addition to motivation, cooking skills were strengthened and nutritional knowledge was imparted. Follow-up visits were carried out after 10 and 20 weeks.
Results
The MoKaRi diet lowered the concentrations of total cholesterol (menu plan group (MP): -15%; menu plan plus fish oil group (MP-FO): -11%), LDL-C (MP: -14%; MP-FO: -16%) and non-high-density lipoprotein cholesterol (MP: -16%; MP-FO: -13%) (p < 0.001). Body weight (MP: -5%; MP-FO: -8%; p < 0.05), waist circumference (MP: -6%; MP-FO: -9%) as well as diastolic blood pressure (MP: -8%; MP-FO: -8%), apolipoprotein A1 (MP: -15%; MP-FO: -20%), apolipoprotein B (MP: -15%; MP-FO: -6%) and glycated hemoglobin A1c (HbA1c) (MP: -1.8%; MP-FO: -3.6%) were also reduced in both groups after 20 weeks (p < 0.05).
In both intervention groups, a maximum reduction in LDL-c of approx. 26% was achieved within the 20 weeks of intervention. Individual participants achieved a reduction of 45 to 49%. The supplementation of fish oil on top of the menu plans resulted in more substantial effects on body weight (MP: -5% vs. MP-FO: -8%), body fat (MP: -11% vs. MP-FO: -20%), triglycerides (MP: -14% vs. MP-FO: -28%), high-sensitivity C-reactive protein (MP: -19% vs. MP-FO: -43%) and HbA1c (MP: -1.8% vs. MP-FO:: 3.6%; p < 0.05).
Conclusions
The MoKaRi diet resulted in a significant reduction of cardiometabolic risk factors. Our data highlights the additional benefit of the combination between menu plans and fish oil supplementation, which resulted in more substantial effects on body weight, BMI, TG, HbA1c and hs-CRP.
ClinicalTrials.gov Identifier
NCT02637778.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12944-025-02500-1.
Publication and source details
Original title: Reduction of cardiovascular risk factors by the diet: Evaluation of the MoKaRi concept by a parallel-designed randomized study
Christine Dawczynski; Timo Drobner; Thomas Weidauer; Peter Schlattmann; Michael Kiehntopf; Daniela Weber; Tilman Grune; Winfried März; Marcus E. Kleber; Stefan Lorkowski
Lipids in Health and Disease · 2025
© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.https://doi.org/10.13039/501100002347Bundesministerium für Bildung und Forschung01EA1411C01EA1411C01EA1411C01EA1411C01EA1411CDawczynski Christine Drobner Timo Weidauer Thomas Kiehntopf Michael Lorkowski Stefan Friedrich-Schiller-Universität Jena (1010)Open Access funding enabled and organized by Projekt DEAL.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T06:30:12.888585+00:00
DOI: 10.1186/s12944-025-02500-1 · PMC11889781